Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,407 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dysplasia Mild Clear all

Conditions: COVID-19
Interventions: Sotrovimab; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 0 Days to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Cullman, Alabama • Mesa, Arizona

Conditions: Mild Cognitive Impairment, Adherence, Patient, Ketosis
Interventions: Motivational Interviewing-Cognitive Behavioral Therapy Ketogenic Nutrition Adherence Program, Ketogenic Nutrition Program; Behavioral · Other
Lead sponsor: Florida State University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Optical Coherence Tomography; Diagnostic Test
Lead sponsor: University of California, Davis; Other
Eligibility: 50 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Osteoarthritis (OA) of the Hip, Osteoarthritis (OA) of the Knee, Osteoarthritis (OA) of the Shoulder, Osteoarthritis, Mild Cognitive Impairment, MCI, Mild Cognitive Impairment (MCI), Dementia
Interventions: Well-formulated ketogenic diet; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 55 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fairway, Kansas

Conditions: Mild to Moderate Alzheimer's Disease
Interventions: CT1812, Placebo; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more

Conditions: Mild Alzheimer's Disease
Interventions: LNK-754, Placebo; Drug
Lead sponsor: Link Medicine Corporation; Industry
Eligibility: 55 Years and older
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 7
States / cities: Phoenix, Arizona • Long Beach, California • Miami, Florida + 4 more

Conditions: Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Sheffield, Alabama + 12 more

Conditions: Mild Cognitive Impairment
Interventions: Transcutaneous vagal nerve stimulation, Sham stimulation; Device
Lead sponsor: University of Florida; Other
Eligibility: 60 Years to 89 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Gainesville, Florida

Conditions: Brain Concussion, Brain Injuries
Interventions: HS-1000 recording; Device
Lead sponsor: HeadSense Medical; Industry
Eligibility: 13 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Interventions: grape seed polyphenolic extract, resveratrol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
Interventions: PF-08103402, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rosacea
Interventions: B244, Vehicle; Biological
Lead sponsor: AOBiome LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 9
States / cities: Clearwater, Florida • Miami, Florida • Miramar, Florida + 4 more

Conditions: Healthy Volunteer
Interventions: danoprevir, ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: PostPartum Depression
Interventions: MamaLift Plus, Digital Sham App; Device
Lead sponsor: Healthcare Innovation Technology Lab; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Alzheimer's Disease
Interventions: BIIB037, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Delray Beach, Florida • Orlando, Florida • Beachwood, Ohio

Conditions: Alzheimer's Disease
Interventions: Crenezumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 66
States / cities: Phoenix, Arizona • Encino, California • Long Beach, California + 56 more

Conditions: Dementia, Mild Cognitive Impairment
Interventions: Medication therapy management; Behavioral
Lead sponsor: Daniela Moga; Other
Eligibility: 60 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Mild Asthma, Allergy
Interventions: inhaled allergen challenge; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acne Vulgaris
Interventions: Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA); Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years and older
Enrollment: 879 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 16
States / cities: Mobile, Alabama • Boulder, Colorado • Newnan, Georgia + 13 more

Conditions: Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Interventions: I-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan; Drug · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dry Eye
Interventions: Restylane Defyne; Device
Lead sponsor: John C Meyer, MD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Mild Traumatic Brain Injury
Interventions: Training in Virtual Reality, Training on a computer screen; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Neurocognitive Disorders, Cognitive Dysfunction, Traumatic Brain Injury, Multiple Sclerosis, Mild Cognitive Impairment
Interventions: CRT, CBT, Modifiable lifestyle factors, Usual care Psychoeducation; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Acute Liver Failure, Intracranial Hypertension
Interventions: Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero; Device
Lead sponsor: Copenhagen University Hospital, Rigshospitalet; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

MI-CBT Adherence Program for Lifestyle Interventions in Older Adults

Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?

Ketogenic Diet to Reduce Osteoarthritis Pain in MCI

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease

Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation

An Evaluation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion

BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Curio Digital Therapy for the Treatment of Post-partum Depression

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

Assessment of Medication Optimization in Rural Kentucky Appalachian Patients With Mild Cognitive Impairment or Dementia

Study of Dust Mite Inhalation in Humans

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

DaTSCAN Imaging in Aging and Neurodegenerative Disease

A Study to Evaluate the Safety and Effectiveness Assessments of Restylane-Defyne for Punctual Occlusion

Enhancing Brain Training With Virtual Reality

A Pilot Randomized Controlled Trial: CoINTEGRATE

Hypothermia to Prevent High Intracranial Pressure in Patients With Acute Liver Failure